MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!
Journey Colab is unlocking the science of psychedelics to build a new model of addiction care combining the potential of neuroplasticity-promoting therapeutics with psychotherapy and community support. Our lead compound is synthetic Mescaline HCl for patients with alcohol use disorder (AUD), who are in desperate need of durable remission from this chronic, relapsing condition. Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care.